**Multiple U.S. and international IPOs are scheduled to price and begin trading in late September and October 2026, including Oura Inc. (targeting ~$2.1 billion raise on Nasdaq Sept. 30), Accelevation Holdings (~$660 million), and several smaller filings such as Encore Medical and direct listings.** With 249 IPOs already completed on U.S. exchanges through late September, the active pipeline of S-1 filings and priced deals through year-end makes additional debuts before December 31, 2026, the near-certain outcome priced by traders. Market-implied odds reflect this visibility, supported by reopened IPO windows, improving equity valuations, and steady deal flow in biotech, tech infrastructure, and consumer sectors. Key near-term catalysts include final pricing dates and any regulatory clearances for larger names still in registration. While last-minute withdrawals remain possible in volatile conditions, the breadth of confirmed activity through Q4 leaves little scope for a zero-IPO finish to the year.